Roivant Sciences Ltd. - 8-K Filing
Roivant Sciences Ltd. filed an 8-K on May 20, 2026 to report its financial results for the fourth quarter and fiscal year ended March 31, 2026, along with a business update. The company reported consolidated cash, cash equivalents, and marketable securities of $4.3 billion as of March 31, 2026. Key developments include positive preliminary data from an IMVT-1402 trial in difficult-to-treat rheumatoid arthritis (ACR20 response rate of 72.7% at Week 16), Breakthrough Therapy Designation for brepocitinib in cutaneous sarcoidosis, and a $2.25 billion settlement with Moderna. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ROIV